Abbott Laboratories
126.61-0.57 (-0.45%)
Oct 28, 4:00:02 PM EDT · NYSE · ABT · USD
Key Stats
Market Cap
220.36BP/E (TTM)
15.91Basic EPS (TTM)
7.96Dividend Yield
0.02%Recent Filings
8-K
10-Q
Q2 FY2025 results
Abbott Laboratories posted solid Q2 results, with net sales climbing 7.4% year-over-year to $11.1B, driven by 13.4% growth in Medical Devices while Diagnostics dipped 1.0% from fading COVID-19 tests. Operating earnings rose 23.0% to $2.1B, lifting diluted EPS 36.5% to $1.01 on steady shares around 1.75M; gross margins expanded to 52.7% from 51.1% via efficiency gains. Year-to-date sales hit $21.5B, up 5.7%, with operating cash flow at $3.5B yielding free cash flow of $2.5B (derived) after $1.0B capex. Cash sits at $7.0B, total debt $13.4B after repaying $1.0B notes in March, and restructuring trimmed costs by $104M in severance. Medical Devices dominates at 48% of sales. Yet litigation over infant formula risks lingers.
8-K
Abbott Q2 sales surge
Abbott Laboratories reported second-quarter 2025 sales of $11.1 billion, up 7.4% on a reported basis and 6.9% organically, driven by 13.4% growth in Medical Devices while Diagnostics dipped 1.0% amid fading COVID-19 testing demand. Adjusted diluted EPS hit $1.26, reflecting double-digit gains and 100 basis point margin expansion to 22.9%. Momentum builds. Full-year guidance calls for 7.5%-8.0% organic sales growth excluding COVID tests and adjusted EPS of $5.10-$5.20.
8-K
Allen retires after transition
Abbott Laboratories announced on April 25, 2025, that Hubert L. Allen, its Executive Vice President, General Counsel, and Secretary, plans to retire following a transition period. This leadership shift in legal affairs could prompt scrutiny of succession plans. No replacement or timeline details disclosed. Smooth handover essential.
10-Q
Q1 FY2025 results
Abbott's Q1 sales climbed 4.0% year-over-year to $10.4B, with medical devices surging 9.9% on strong diabetes care and structural heart demand, while diagnostics dipped 7.2% from fading COVID tests. Operating earnings jumped 22.1% to $1.7B, lifting diluted EPS to $0.76 from $0.70, as gross margins expanded to 52.8% via efficiency gains. Cash from operations hit $1.4B, funding $484M capex for $933M free cash flow (derived), yet debt eased to $13.2B after repaying $1.0B notes. Restructuring in diagnostics and devices notched $46M charges but aims at sharper focus. Solid balance sheet holds $6.5B cash. Litigation over infant formula risks linger.
ABBV
AbbVie Inc.
227.54-0.49
BDX
Becton, Dickinson and Company
184.21-2.83
BIO
Bio-Rad Laboratories, Inc.
330.42-5.70
BMRA
Biomerica, Inc.
2.93-0.03
BRKR
Bruker Corporation
38.72+0.08
BSX
Boston Scientific Corporation
100.97-1.46
CODX
Co-Diagnostics, Inc.
0.57-0.69
JNJ
Johnson & Johnson
186.93-3.37
MASI
Masimo Corporation
146.41-1.59
MDT
Medtronic plc.
93.23-0.90